[Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)].
The pharmacokinetics of Ginkgolide A, Ginkgolide B and Bilobalide, which are compounds extracted from the dried leaves of the Ginkgo biloba tree, were investigated in 12 young healthy volunteers (six men and six women; mean +/- SD age = 25 +/- 5 years) after single-dose administration of Ginkgo biloba extract. Subjects were given, on three occasions, Ginkgo biloba extract as a solution either orally (in fasting conditions and after a standard meal) or intravenously; corresponding to single doses of Ginkgolide A, Ginkgolide B and Bilobalide ranging from 0.90 mg to 3.36 mg. After each dosing, blood and urine samples were collected for up to 36 h and 48 h, for measurements of Ginkgolide A, Ginkgolide B and Bilobalide. Plasma and urine concentrations of these compounds were quantitatively measured by gas chromatography/mass spectrometry using negative chemical ionization, by applying a very sensitive method which allowed plasma concentrations as low as 0.2 ng/ml of each compound to be measured. When given orally, while fasting, the extents of bioavailability are high, as shown by bioavailability coefficients (FAUC) mean (+/- SD) values equal to 0.80 (+/- 0.09), 0.88 (+/- 0.21) and 0.79 (+/- 0.30) for Ginkgolide A, Ginkgolide B and Bilobalide respectively. Food intake does not change AUC quantitatively but increases Tmax. For the three compounds of interest, after oral dosing while fasting, differences can be noted for the elimination half-lives (T1/2Z), which exhibit mean values equal to 4.50, 10.57 and 3.21 h, as well as mean residence times (MRT), equal to 5.86, 11.25 and 4.89 h, for Ginkgolide A, Ginkgolide B and Bilobalide respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Fourtillan
J B
JB
CEMAF, Poitiers.
Brisson
A M
AM
Girault
J
J
Ingrand
I
I
Decourt
J P
JP
Drieu
K
K
Jouenne
P
P
Biber
A
A
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D018592:Cross-Over Studies; D003517:Cyclopentanes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004224:Diterpenes; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005663:Furans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D020441:Ginkgo biloba; D046934:Ginkgolides; D015989:Healthy Worker Effect; D006801:Humans; D007275:Injections, Intravenous; D007783:Lactones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D010936:Plant Extracts / Q000008:administration & dosage / Q000493:pharmacokinetics; D000096983:Ginkgo Extract
D003517:Cyclopentanes; D004224:Diterpenes; D005343:Fibrinolytic Agents; D005663:Furans; D046934:Ginkgolides; D007783:Lactones; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract; C045856:ginkgolide B; C073710:bilobalide
Propriétés pharmacocinétiques du Bilobalide et des Ginkgolides A et B chez le sujet sain après administrations intraveineuses et orales d'extrait de Ginkgo biloba (EGb 761).